Finding your next opportunity shouldn’t require piecing together multiple databases, alerts and research tools.
Fundz combines its own funding and M&A intelligence with hiring, leadership and other business signals into one connected view of each company, ranks opportunities against your ideal customer profile, and delivers the evidence and verified contacts to act on. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
CNS Pharmaceuticals, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
cnspharma.comAI Executive Summary
AI-powered analysis of 8-K filing content
CNS Pharmaceuticals stockholders approved amendments to the 2020 Equity Plan at the September 30, 2026 Annual Meeting, increasing authorized shares by 650,000 to a total of 765,061 shares available for equity compensation, enhancing the company's ability to incentivize employees and attract talent.
Key Takeaways
Stockholders approved a 650,000 share increase to the 2020 Equity Plan at the Annual Meeting on September 30, 2026
Total authorized shares under the plan now stands at 765,061 shares
2 more takeaways
Filing Overview
What This Means
CNS Pharmaceuticals, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.